Fulltext

In vitro susceptibility of Actinobaculum schaalii to 12 antimicrobial agents and molecular analysis of fluoroquinolone resistance

Cattoir, Vincent ; Varca, Alexandre ; Greub, Gilbert ; Prod'hom, Guy ; Legrand, Patrick ; Lienhard, Reto

In: Journal of Antimicrobial Chemotherapy, 2010, vol. 65, no. 12, p. 2514-2517

Ajouter à la liste personnelle
    Titre
    • In vitro susceptibility of Actinobaculum schaalii to 12 antimicrobial agents and molecular analysis of fluoroquinolone resistance
    Auteur
    • Cattoir, Vincent. Service de Microbiologie, CHU Côte de Nacre, Caen, France
    • Varca, Alexandre. ADMED Microbiologie, La Chaux-de-Fonds, Switzerland
    • Greub, Gilbert. Bacteriology Laboratory, Institute of Microbiology, University of Lausanne and University Hospital Center, Lausanne, Switzerland
    • Prod'hom, Guy. Bacteriology Laboratory, Institute of Microbiology, University of Lausanne and University Hospital Center, Lausanne, Switzerland
    • Legrand, Patrick. Service de Bactériologie-Virologie-Hygiène, CHU Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France
    • Lienhard, Reto. ADMED Microbiologie, La Chaux-de-Fonds, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Journal of Antimicrobial Chemotherapy, 2010, vol. 65, no. 12, p. 2514-2517. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:293529
    Summary
    Objectives To assess the in vitro susceptibility of Actinobaculum schaalii to 12 antimicrobial agents as well as to dissect the genetic basis of fluoroquinolone resistance. Methods Forty-eight human clinical isolates of A. schaalii collected in Switzerland and France were studied. Each isolate was identified by 16S rRNA sequencing. MICs of amoxicillin, ceftriaxone, gentamicin, vancomycin, clindamycin, linezolid, ciprofloxacin, levofloxacin, moxifloxacin, co-trimoxazole, nitrofurantoin and metronidazole were determined using the Etest method. Interpretation of results was made according to EUCAST clinical breakpoints. The quinolone-resistance-determining regions (QRDRs) of gyrA and parC genes were also identified and sequence analysis was performed for all 48 strains. Results All isolates were susceptible to amoxicillin, ceftriaxone, gentamicin, clindamycin (except three), vancomycin, linezolid and nitrofurantoin, whereas 100% and 85% were resistant to ciprofloxacin/metronidazole and co-trimoxazole, respectively. Greater than or equal to 90% of isolates were susceptible to the other tested fluoroquinolones, and only one strain was highly resistant to levofloxacin (MIC ≥32 mg/L) and moxifloxacin (MIC 8 mg/L). All isolates that were susceptible or low-level resistant to levofloxacin/moxifloxacin (n = 47) showed identical GyrA and ParC amino acid QRDR sequences. In contrast, the isolate exhibiting high-level resistance to levofloxacin and moxifloxacin possessed a unique mutation in GyrA, Ala83Val (Escherichia coli numbering), whereas no mutation was present in ParC. Conclusions When an infection caused by A. schaalii is suspected, there is a risk of clinical failure by treating with ciprofloxacin or co-trimoxazole, and β-lactams should be preferred. In addition, acquired resistance to fluoroquinolones more active against Gram-positive bacteria is possible